Group 1 - The core viewpoint of the article is that Beijing Xiantong International Pharmaceutical Technology Co., Ltd. (Xiantong Pharmaceutical) submitted its Hong Kong IPO prospectus on May 26, 2025, which became invalid after six months on November 26, 2025, with CICC and CITIC Securities as joint sponsors [1] - Xiantong Pharmaceutical is a leader in the Chinese radiopharmaceutical market, focusing on the development and commercialization of radiopharmaceuticals with the potential to be the first listed or best-in-class in China [2] - As of the last feasible date (May 16, 2025), Xiantong Pharmaceutical's pipeline focuses on three major areas: oncology, neurodegenerative diseases, and cardiovascular diseases, including 15 assets, with four core products: XTR008, XTR006, XTR004, and XTR003 [2]
新股消息 | 先通医药港股IPO招股书失效
智通财经网·2025-11-26 23:14